Dual repair modulation reverses Temozolomide resistance in vitro.
Authors
Barvaux, Vincent ARanson, Malcolm R
Brown, Robert
McElhinney, R Stanley
McMurry, T Brian H
Margison, Geoffrey P
Affiliation
Paterson Institute for Cancer Research and Christie Hospital, Manchester, United Kingdom.Issue Date
2004-02
Metadata
Show full item recordAbstract
Temozolomide is an alkylating agent that mediates its cytotoxic effects via O(6)-methylguanine (O(6)-meG) adducts in DNA and their recognition and processing by the postreplication mismatch repair system (MMR). O(6)-meG adducts can be repaired by the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase (MGMT), which therefore constitutes a major resistance mechanism to the drug. Resistance to Temozolomide can also be mediated by loss of MMR, which is frequently mediated by methylation of the hMLH1 gene promoter. Methylation of hMLH1 can be reversed by treatment of cells with 5-aza-2'-deoxycytidine, while the MGMT pseudosubstrate O(6)-(4-bromothenyl)guanine (PaTrin-2) can deplete MGMT activity. Using a drug-resistant cell line which expresses MGMT and has methylated hMLH1, we show that while either of these treatments can individually sensitize cells to Temozolomide, the combined treatment leads to substantially greater sensitization. The increased sensitization is not observed in matched MMR proficient cells.Citation
Dual repair modulation reverses Temozolomide resistance in vitro. 2004, 3 (2):123-7 Mol. Cancer Ther.Journal
Molecular Cancer TherapeuticsPubMed ID
14985452Type
ArticleLanguage
enISSN
1535-7163Related articles
- Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
- Authors: Barvaux VA, Lorigan P, Ranson M, Gillum AM, McElhinney RS, McMurry TB, Margison GP
- Issue date: 2004 Oct
- Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
- Authors: Liu L, Schwartz S, Davis BM, Gerson SL
- Issue date: 2002 Jun 1
- O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
- Authors: Clemons M, Kelly J, Watson AJ, Howell A, McElhinney RS, McMurry TB, Margison GP
- Issue date: 2005 Nov 14
- A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
- Authors: Alvino E, Castiglia D, Caporali S, Pepponi R, Caporaso P, Lacal PM, Marra G, Fischer F, Zambruno G, Bonmassar E, Jiricny J, D'Atri S
- Issue date: 2006 Oct
- Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
- Authors: von Bueren AO, Bacolod MD, Hagel C, Heinimann K, Fedier A, Kordes U, Pietsch T, Koster J, Grotzer MA, Friedman HS, Marra G, Kool M, Rutkowski S
- Issue date: 2012 Oct 9